Scholarlink

Background <p>Based on current knowledge, omega-3 fatty acids help to reduce the concentration of C-reactive protein (CRP). However, the dose–response effect and the strength of this effect are not entirely clear.</p> Methods <p>We systematically searched and screened databases to include eligible studies. This study incorporates a random effect, as well as dose–response meta-analyses using a restricted cubic spline model.</p> Results <p>Forty randomized clinical trials were analyzed. Results demonstrated significant non-linear dose–response efficacy in the reduction of CRP concentration in patients with cardiovascular disease, metabolic syndrome, and hypertension up to 1200 mg/day of EPA and DHA. In addition, there was a linear decrease in CRP concentration in the dyslipidemia population. The meta-analysis results did not show any significant reduction of CRP in overweight and obese participants, and the dose–response analysis failed to show any apparent reduction. In type 2 diabetes, pooling the results revealed a significant reduction in CRP; however, the combination of EPA and DHA failed to show significant dose–response efficacy in changing CRP concentration.</p> Conclusion <p>1200 mg/day of EPA and DHA may help to reduce CRP concentration in patients with cardiometabolic disorders. This reduction is clinically significant, and thus intervention with omega-3 fatty acids should be considered for this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dose-dependent effects of omega-3 polyunsaturated fatty acids on C-reactive protein concentrations in cardiometabolic disorders: a dose–response meta-analysis of randomized clinical trials

  • 期刊论文

  • 发表日期：

    2025年4月22日

查看全文
  • Manoochehr Amin Amlashi,
  • Atefeh Payahoo,
  • Saber Jafari Maskouni,
  • Elaheh Dehghani,
  • Mahtab Karami Talandashti,
  • Yeganeh Ghelichi,
  • Mahya Nikoumanesh,
  • Soroush Rezvani,
  • Hossein Shahinfar,
  • Farzad Shidfar

摘要

Background

Based on current knowledge, omega-3 fatty acids help to reduce the concentration of C-reactive protein (CRP). However, the dose–response effect and the strength of this effect are not entirely clear.

Methods

We systematically searched and screened databases to include eligible studies. This study incorporates a random effect, as well as dose–response meta-analyses using a restricted cubic spline model.

Results

Forty randomized clinical trials were analyzed. Results demonstrated significant non-linear dose–response efficacy in the reduction of CRP concentration in patients with cardiovascular disease, metabolic syndrome, and hypertension up to 1200 mg/day of EPA and DHA. In addition, there was a linear decrease in CRP concentration in the dyslipidemia population. The meta-analysis results did not show any significant reduction of CRP in overweight and obese participants, and the dose–response analysis failed to show any apparent reduction. In type 2 diabetes, pooling the results revealed a significant reduction in CRP; however, the combination of EPA and DHA failed to show significant dose–response efficacy in changing CRP concentration.

Conclusion

1200 mg/day of EPA and DHA may help to reduce CRP concentration in patients with cardiometabolic disorders. This reduction is clinically significant, and thus intervention with omega-3 fatty acids should be considered for this population.